Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Waxman/Hatch Reform Bill Needed Despite FDA’s Rule – McCain, Schumer

Executive Summary

Legislation to reform the generic drug approval process will still be needed following issuance of FDA's final rule, Sens. John McCain (R-Ariz.) and Charles Schumer (D-N.Y.) said

You may also be interested in...



Medicare Law Puts Rx In Spotlight Of Presidential Campaign Politics

Restrictions on direct-to-consumer advertising of prescription drugs are among health care proposals being offered by 2004 Democratic presidential candidates

Medicare Law Puts Rx In Spotlight Of Presidential Campaign Politics

Restrictions on direct-to-consumer advertising of prescription drugs are among health care proposals being offered by 2004 Democratic presidential candidates

Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings

A bipartisan Senate bill would encourage earlier ANDA filings by generics firms to head off new innovator patent listings and secure sole rights to 180-day exclusivity

Related Content

UsernamePublicRestriction

Register

PS041546

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel